About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its investigational RNAi therapeutics focus on Strategic Therapeutic Areas (STArs), including Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases. Its Genetic medicines include Patisiran (ALN-TTR02) and Fitusiran (ALN-AT3), and additional genetic programs, including ALN-AAT.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: ALNY
- CUSIP: 02043Q10
- Previous Close: $46.62
- 50 Day Moving Average: $42.20
- 200 Day Moving Average: $50.61
- 52-Week Range: $31.38 - $80.11
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -10.82
- P/E Growth: -0.20
- Market Cap: $4.37B
- Outstanding Shares: 86,013,000
- Beta: 2.69
- Net Margins: -869.63%
- Return on Equity: -37.25%
- Return on Assets: -30.67%
Companies Related to Alnylam Pharmaceuticals:
- Debt-to-Equity Ratio: 0.15%
- Current Ratio: 9.14%
- Quick Ratio: 9.14%
What is Alnylam Pharmaceuticals' stock symbol?
Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."
Where is Alnylam Pharmaceuticals' stock going? Where will Alnylam Pharmaceuticals' stock price be in 2017?
16 brokers have issued 12 month price objectives for Alnylam Pharmaceuticals' shares. Their predictions range from $34.00 to $106.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $65.44 in the next year.
When will Alnylam Pharmaceuticals announce their earnings?
Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.
What are analysts saying about Alnylam Pharmaceuticals stock?
Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:
Chardan Capital analysts commented, "We now seen Alnylam as the leader in the clinical HBV RNAi therapy space. As discussed in our 14 October 2016 company note for Arbutus (Buy), we believe ARB-1467 has demonstrated at best mediocre phase IIa results that were predictable based on inferior preclinical data relative to Alnylam’s RNAi asset, ALN-HBV . Additionally, ALN-HBV has a favorable dosing route in subcutaneous delivery compared to Arbutus’ ARB-1467 and ARB-1740, which are administered by intravenous injection. With Arrowhead moving to preclinical development in HBV , we now view Alnylam as the leader in the space." (11/30/2016)
According to Zacks Investment Research, "Alnylam is a development-stage biopharmaceutical company focused on the development of RNAi-based therapeutics. The company expects to achieve the profile of three marketed products by the end of 2020. Investor focus should be on the company's progress with its late-stage pipeline candidate, patisiran. Meanwhile, Alnylam’s RNAi technology has allowed the company to ink collaborations with leading pharmaceutical and life sciences companies like Novartis, Roche, Monsanto and Sanofi. These deals will not only provide it with funds but also take its RNAi technology outside the core focus area. Estimate movement has been mixed lately ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters. However, the discontinuation of the phase III ENDEAVOUR study on revusiran, following the Data Monitoring Committee’s recommendation (DMC) is disappointing." (10/25/2016)
Needham & Company LLC analysts commented, "Alnylam announced additional data from its ongoing fitusiran Phase 1/2 trial in Hemophilia. Emerging safety and efficacy profile is consistent w/ prior clinical data and point to a differentiated once-monthly agent. Phase 3 initiation, however, has been pushed into 2017 (was 2H16). Regulators are seeking additional information around dose. Mgmt expects to complete dose-escalation in Hemophilia pts w/ Inhibitors later this yr." (7/25/2016)
Who owns Alnylam Pharmaceuticals stock?
Alnylam Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Baillie Gifford & Co. (3.86%), State Street Corp (2.75%), RTW Investments LP (0.92%), 12 West Capital Management LP (0.81%) and Arrowpoint Asset Management LLC (0.81%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, David E I Pyott, David-Alexandre C Gros, Dennis A Ausiello, John Maraganore, Kevin P Starr, Michael W Bonney, Paul Schimmel, Philip A Sharp and Sanofi.
Who sold Alnylam Pharmaceuticals stock? Who is selling Alnylam Pharmaceuticals stock?
Alnylam Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., RTW Investments LP, Allianz Asset Management AG, Baillie Gifford & Co., Oxford Asset Management, Credit Agricole S A, State Board of Administration of Florida Retirement System and Van ECK Associates Corp. Company insiders that have sold Alnylam Pharmaceuticals stock in the last year include Akshay Vaishnaw, John Maraganore and Philip A Sharp.
Who bought Alnylam Pharmaceuticals stock? Who is buying Alnylam Pharmaceuticals stock?
Alnylam Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including 12 West Capital Management LP, Arrowpoint Asset Management LLC, Boxer Capital LLC, Frontier Capital Management Co. LLC, ARK Investment Management LLC, Perceptive Advisors LLC, Russell Investments Group Ltd. and A.R.T. Advisors LLC. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include David E I Pyott, David-Alexandre C Gros, Michael W Bonney and Sanofi.
How do I buy Alnylam Pharmaceuticals stock?
Shares of Alnylam Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Alnylam Pharmaceuticals stock cost?
One share of Alnylam Pharmaceuticals stock can currently be purchased for approximately $51.31.